Dalbavancin
Treatment for Skin and Structure InfectionVicuron Pharmaceuticals Receives Issued Patent for Dalbavancin Dosing by U.S. Patent and Trademark Office
KING OF PRUSSIA, Penn., June 2, 2005 -- Vicuron Pharmaceuticals Inc. today announced that the United States Patent and Trademark Office issued patent number 6,900,175 entitled "Methods of Administrating Dalbavancin For Treatment Of Bacterial Infections." The patent, which will expire in December 2023, relates to a novel dosing regimen for dalbavancin. The dalbavancin New Drug Application (NDA) for the treatment of complicated skin and soft tissue infections (cSSTIs) including the most difficult to treat strain of staphylococcus, methicillin-resistant staphylococcus aureus (MRSA) is currently under review with the U.S. Food and Drug Administration (FDA).
About Dalbavancin
Dalbavancin is a novel second-generation lipoglycopeptide agent
that belongs to the same class as vancomycin. Vancomycin is one of
the few treatments available to hospital patients infected with
difficult-to-treat strains of Staphylococcus bacteria, or Staph
known as MRSA (methicillin- resistant Staphylococcus aureus) and
MRSE (methicillin-resistant Staphylococcus epidermidis).
Dalbavancin has been specifically designed as an improved
alternative to vancomycin.
About Vicuron Pharmaceuticals
Vicuron Pharmaceuticals is a biopharmaceutical company focused on
discovering, developing, manufacturing and commercializing vital
medicine for seriously ill patients. The company has two New Drug
Applications pending with the U.S. Food and Drug Administration for
its lead products, dalbavancin, a novel intravenous antibiotic for
the treatment of serious Gram-positive infections, and
anidulafungin, a novel antifungal agent. Vicuron's versatile
research engine integrates industry-leading expertise in functional
genomics, mechanism-based drug design and combinatorial and
medicinal chemistry. These approaches are yielding promising novel
and next-generation compounds, many of which are in the later
stages of preclinical development. In addition, the company has
research collaborations with leading pharmaceutical companies, such
as Pfizer.
Related Articles:
Pfizer Receives Approvable Letter from FDA for Dalbavancin - December 21, 2007
Vicuron Pharmaceuticals Announces Extension of FDA Review of Dalbavancin New Drug Application - May 11, 2005
Vicuron Pharmaceuticals Granted Priority Review of Dalbavancin NDA by FDA in Complicated Skin and Soft Tissue Infections - February 24, 2005
Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug Administration - December 21, 2004
New Drug Applications Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
